An investigational targeted therapy developed by Bristol Myers Squibb and SystImmune reduced the relative risk of disease progression or death by 59% compared to standard chemotherapy in patients with previously treated, advanced breast cancer. The late-breaking results from the Phase 3 PANKU-Breast01 study were presented at the European Society for Medical Oncology (ESMO) 2026 Annual Congress in Madrid on October 23, 2026, and simultaneously published in The Lancet, according to Bristol Myers Squibb.

The drug, izalontamab brengitecan—commonly referred to as iza-bren—was tested in patients with unresectable locally advanced, recurrent, or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer who had already undergone at least one prior round of chemotherapy. While the findings demonstrate a clear delay in tumor growth, researchers note that overall survival data remain immature and the medication is not yet approved for use in the United States.

Key Findings from the PANKU-Breast01 Study

The randomized Phase 3 trial (NCT06343948) evaluated 383 patients, with 190 assigned to receive iza-bren and 193 assigned to receive a physician's choice of standard chemotherapy. The trial results were reported by Sichuan Biokin Pharmaceutical, the China-based parent company of SystImmune.

At a prespecified interim analysis, an independent review panel found that patients receiving iza-bren lived a median of 8.2 months without their cancer worsening, more than double the 4.0 months observed in the chemotherapy control group. According to Bristol Myers Squibb, this outcome corresponds to a hazard ratio of 0.41 (95% CI 0.33–0.53; p<0.0001) after a median follow-up of 15.2 months, while Reuters reports the same 383-patient enrollment and median progression-free survival figures in its coverage of how the drug slows disease progression without detailing the confidence interval or follow-up duration.

Beyond slowing the spread of the disease, the targeted drug shrank tumors in twice as many patients as traditional treatment. The confirmed objective response rate reached 40.5% in the iza-bren group compared to 20.2% among those receiving standard chemotherapy, according to Pharmaphorum and Indian Pharma Post. Treatment discontinuations caused by adverse side effects remained low across both groups.

How the Dual-Acting Antibody-Drug Conjugate Works

Iza-bren (formerly known as BL-B01D1) belongs to a class of targeted oncology treatments called antibody-drug conjugates (ADCs). Unlike conventional chemotherapy, which circulates broadly throughout the body and attacks both healthy and cancerous rapidly dividing cells, ADCs are engineered to attach directly to specific proteins on the surface of tumor cells before releasing a toxic payload inside them.

What sets iza-bren apart from earlier drugs in this class is its bispecific design. Rather than seeking out a single target, it simultaneously binds to two distinct receptors: EGFR (epidermal growth factor receptor) and HER3. Oncologists and drug developers have hypothesized that blocking both EGFR and HER3 at the same time can improve treatment effectiveness and help overcome the cellular resistance that often develops against standard EGFR-directed therapies.

"While there have been advances in the treatment landscape for HR-positive, HER2-negative advanced breast cancer, options can become increasingly limited as patients progress through available therapies, with most ultimately relying on chemotherapy," said Professor Binghe Xu of the Chinese Academy of Medical Sciences. "PANKU-Breast01 provides encouraging evidence for a new therapeutic approach."

Context and Strategic Scope of the Drug

Bristol Myers Squibb and SystImmune are co-developing iza-bren for markets outside of mainland China. Bristol Myers Squibb previously paid $800 million upfront to secure global rights to the medication in a licensing agreement that could reach up to $8.4 billion if specific regulatory and commercial milestones are achieved. Industry analysts have projected that peak annual sales for the drug could reach between $3 billion and $5 billion or more, depending on how many cancer indications it ultimately secures, making it a critical asset for Bristol Myers Squibb before its $10 billion-a-year immunotherapy Opdivo loses patent protection around 2028.

In China, where the medicine is distributed by Sichuan Biokin Biopharmaceutical, the National Medical Products Administration (NMPA) approved iza-bren earlier in 2026 for recurrent or metastatic nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma. Earlier this year at the American Society of Clinical Oncology (ASCO) meeting, the companies also shared positive Phase 3 data from the PANKU-Breast02 trial in triple-negative breast cancer and the PANKU-Esophagus01 trial in esophageal cancer, with data from the PANKU-Lung01 study in EGFR-mutated non-small cell lung cancer also scheduled for presentation at ESMO.

What This Means for Patients and US Healthcare

For patients and families following breast cancer research, it is important to understand the distinction between the statistical endpoints reported in clinical trials. While Bristol Myers Squibb characterizes the primary finding as a 59% reduction in the risk of disease progression or death based on progression-free survival, Reuters describes the benefit specifically as slowing disease progression. Both descriptions reflect the same underlying reality: the 59% figure measures how well the drug delays tumor growth or death during the study window, rather than proving a 59% drop in mortality alone.

Does the benefit extend overall survival?

At the time of this interim analysis, overall survival data—which track whether patients taking the experimental drug ultimately live longer overall than those taking standard chemotherapy—remained immature. Patients in the trial will continue to be monitored to determine if the 8.2-month progression-free advantage translates into a verified long-term survival benefit.

What is known about safety and side effects?

Conference summaries noted that treatment discontinuations due to side effects were low in both the iza-bren arm and the chemotherapy control arm. However, detailed breakdowns of specific serious adverse events, dose reductions, and full tolerability profiles are evaluated by regulatory agencies during formal review processes.

Is iza-bren available to patients in the United States?

No. Outside of its specific approvals in China for nasopharyngeal and esophageal cancers, iza-bren remains an investigational medication. The PANKU-Breast01 trial was conducted in China, and the results do not represent U.S. Food and Drug Administration (FDA) approval, clinical availability in the United States, or a change to current American oncology guidelines. Before the medication can be prescribed to U.S. breast cancer patients outside of a clinical trial, regulators generally require mature data and evidence demonstrating how the treatment performs in U.S.-inclusive patient populations alongside domestic standards of care.

Sources